Overview

Doxycycline in Type II Diabetes

Status:
RECRUITING
Trial end date:
2026-04-20
Target enrollment:
Participant gender:
Summary
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by hyperglycemia, weight loss, and cardio-metabolic complications. T2DM develops due to the progression of insulin resistance (IR), impairment of insulin insensitivity, and failure of the pancreatic β-cells to release sufficient amount of insulin in response to glucose burden
Phase:
PHASE1
Details
Lead Sponsor:
Mostafa Bahaa
Treatments:
Doxycycline
Sitagliptin Phosphate